TG Therapeutics, Inc.
TGTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 2.36 | -1.80 | 0.16 | -0.83 |
| FCF Yield | -0.93% | -1.30% | -11.00% | -11.78% |
| EV / EBITDA | 89.13 | 93.58 | -7.43 | -6.70 |
| Quality | ||||
| ROIC | 7.85% | 7.22% | -153.80% | -108.88% |
| Gross Margin | 88.30% | 93.95% | 90.48% | 88.19% |
| Cash Conversion Ratio | -1.73 | -2.48 | 0.89 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | 390.67% | 226.90% | 163.63% | 253.05% |
| Free Cash Flow Growth | -29.12% | 82.17% | 40.49% | -37.78% |
| Safety | ||||
| Net Debt / EBITDA | 1.48 | 0.68 | 0.09 | 0.64 |
| Interest Coverage | 1.75 | 1.64 | -21.42 | -61.15 |
| Efficiency | ||||
| Inventory Turnover | 0.35 | 0.35 | 0.00 | 0.00 |
| Cash Conversion Cycle | 1,190.90 | 1,108.43 | 0.00 | 75.79 |